Academics

Acute Creatine Monohydrate Ingestion and Cognitive Performance ...

Acute Creatine Monohydrate Ingestion and Cognitive Performance ...

Academics NAVIGATION

Acute Creatine Monohydrate Ingestion and Cognitive Performance: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study

LU IRB#: IRB-25-23
PI: Chad Kerksick, PhD

Description of Study

The aim of the research study is to examine the acute effects of a single and 3 days of 30-gram doses of creatine monohydrate on cognitive performance measures in healthy adults.

Location
Exercise and Performance Nutrition Laboratory (Fieldhouse 126)
209 S Kingshighway St
Saint Charles, MO 63301

Number of Visits
6 (5 visits to the lab)

Time Commitment
Visits 1-5: 45-60 minutes
Visit 6: 10 minutes

Points of Contact
Wyatt McLaughlin
epnl@lindenwood.edu

Research Sample Needed

  • 50-60 healthy men and women

Inclusion Criteria

  • Between 18 and 50 years old.
  • In good general health with no unmanaged chronic medical conditions (e.g., hypertension, cardiovascular disease, or neurological disorders).
  • No creatine or cognitive-enhancing supplements (e.g., nootropics) within the past 30 days.
  • Not currently taking medications that impact cognitive function, sleep, or physiological measures (e.g., sedative, stimulants, antidepressants).
  • Must be available to attend all testing visits over 4 consecutive days.
  • Must agree to maintain their usual sleep and physical activity routines throughout the study.
  • Able to consume the supplement at home (or outside the lab) and arrive at the lab within 150-170 minutes post-ingestion.
  • Must report regular sleep patterns (e.g., 6-9 hours per night).
  • No history of shift work or frequent travel across time zones within the past 14 days.

Exclusion Criteria

  • Diagnosed with or receiving treatment for cardiovascular disease, neurological disorders, or psychiatric conditions.
  • Diagnosed with sleep disorders (e.g., insomnia, sleep apnea).
  • Pregnant, breastfeeding, or planning to become pregnant during the study period.
  • Currently using medications known to affect cognitive function, sleep, or physiological outcomes (e.g., sedatives, stimulants, antidepressants).
  • Taken nootropics or other cognitive-enhancing supplements (e.g., modafinil, racetams) within the past 30 days
  • Inability to maintain consistent daily routines during the study period (frequent time zone changes, shift work).
  • Unwilling or unable to attend all study visits or complete required assessments.
  • Non-compliance with the supplementation or data collection protocols.

Are You Eligible?

Information provided here reflects current IRB approval for this research. However, this information may be subject to change and updated accordingly.

Centers & Institutes